GlassScriptPhysician profile
Joseph Dimaria
NPI 1952506230
$4,104.79
in general payments reported to CMS, 2019-2025
28 companies · $48.62 in 2025
The $48.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $76.14 · 2021: $818 · 2022: $1,264 · 2023: $1,516 · 2024: $186 · 2025: $48.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $661.38 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $528.34 | 2020-2023 | Mavyret, Vraylar |
| Gilead Sciences, INC. | $458.05 | 2020-2023 | Descovy |
| Bayer Healthcare Pharmaceuticals INC. | $438.42 | 2021-2023 | |
| Lilly USA, LLC | $287.79 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.68 | 2022-2023 | |
| Biotronik INC. | $195.98 | 2019 | |
| Amgen INC. | $169.85 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $149.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.92 | 2023 | |
| Procept Biorobotics Corporation | $119.04 | 2023 | Aquabeam Robotic System |
| Pfizer INC. | $102.96 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $82.49 | 2024-2025 | Ingrezza |
| Electromed, INC. | $70.35 | 2023-2024 | Smartvest |
| Abbott Laboratories | $66.02 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $60.56 | 2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Teva Pharmaceuticals USA, INC. | $57.18 | 2024 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $56.85 | 2021 | |
| Biogen, INC. | $54.23 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $51.64 | 2021-2024 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $49.52 | 2021-2022 | |
| Shield Therapeutics INC | $22.48 | 2023 | Accrufer |
| Exact Sciences Corporation | $19.28 | 2023 | Cologuard Collection Kit |
| Convatec INC. | $15.24 | 2022 | |
| Grifols USA, LLC | $12.95 | 2023 | Prolastin-C Liquid |
| Amarin Pharma, INC. | $12.80 | 2021 | |
| Dermira, INC. | $11.00 | 2020 | |
| Advanced Oxygen Therapy INC. | $10.36 | 2023 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Dimaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.